header
Image from OpenLibrary

Comparative study of the efficacy and safety of di-peptidyl peptidase inhibitors versus metformin in diabetic hypertensive patients / Dalia Kamal Zaafar Ali ; Supervised Hekma Abdellatif , Abdelrahman Elnaggar , Mohammed F. Elyamany

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Dalia Kamal Zaafar Ali , 2019Description: 137 P. : charts ; 25cmOther title:
  • دراسة مقارنة فعالية و أمان دواء مثبط ثنائي بيبتيدايل بيبتيديز و ميتفورمين في مرضى الداء السكري مرتفعي ضغط الدم [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology Summary: Background: Several trials have reported that dipeptidyl peptidase-4 (DPP-4) inhibitors, used to improve endothelial function in addition to treating type 2 diabetes. The current study investigated the effects of vildagliptin, DPP-4 inhibitor, compared to metformin on endothelial function, and blood pressure through vascular endothelial growth factor (VEGF) modulation in patients with T2DM and hypertension. Methods: This study was designed as a randomized controlled parallel study. A total of 120 volunteers were recruited and allocated into four groups: healthy volunteers,patients recently diagnosed with hypertension and diabetes, patients treated with captopril for hypertension in addition to metformin, and patients treated with captopril in addition to vildagliptin.The percent change in body weight was calculated in addition to serum VEGF levels, blood pressure, glycated haemoglobin (HbA1c), total lipid profile and insulin resistance. Results: At the end of the therapeutic period, the results showed that vildagliptin significantly decreased blood pressure and increased serum VEGF levels, while metformin was more effective at lowering body weight. In comparison with metformin, vildagliptin showed a promising action through its antihypertensive effect via elevating VEGF levels and improving physiological angiogenesis and vasculature
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.09.Ph.D.2019.Da.C (Browse shelf(Opens below)) Not for loan 01010110078612000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.09.Ph.D.2019.Da.C (Browse shelf(Opens below)) 78612.CD Not for loan 01020110078612000

Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology

Background: Several trials have reported that dipeptidyl peptidase-4 (DPP-4) inhibitors, used to improve endothelial function in addition to treating type 2 diabetes. The current study investigated the effects of vildagliptin, DPP-4 inhibitor, compared to metformin on endothelial function, and blood pressure through vascular endothelial growth factor (VEGF) modulation in patients with T2DM and hypertension. Methods: This study was designed as a randomized controlled parallel study. A total of 120 volunteers were recruited and allocated into four groups: healthy volunteers,patients recently diagnosed with hypertension and diabetes, patients treated with captopril for hypertension in addition to metformin, and patients treated with captopril in addition to vildagliptin.The percent change in body weight was calculated in addition to serum VEGF levels, blood pressure, glycated haemoglobin (HbA1c), total lipid profile and insulin resistance. Results: At the end of the therapeutic period, the results showed that vildagliptin significantly decreased blood pressure and increased serum VEGF levels, while metformin was more effective at lowering body weight. In comparison with metformin, vildagliptin showed a promising action through its antihypertensive effect via elevating VEGF levels and improving physiological angiogenesis and vasculature

Issued also as CD

There are no comments on this title.

to post a comment.